Myo-Inositol Clinical Uses

Primary Indication: PCOS Management

The Endocrine Society suggests inositol supplementation as part of comprehensive PCOS management, particularly for patients with poor dietary intake of inositol-containing foods (beans, whole grains, nuts, seeds) 1
The American College of Obstetricians and Gynecologists may recommend metformin for insulin sensitivity, but myo-inositol provides a non-pharmaceutical alternative with superior safety profile 1
Unlike some insulin-sensitizing medications, myo-inositol does not increase weight 1, 2

Myo-inositol inhibits the PI3K pathway activated in bronchial epithelial cells of smokers with dysplasia, correlating with regression of bronchial dysplasia 3
Animal studies demonstrate 40-50% inhibition of carcinogenesis in both induction and postinitiation phases 3
The American College of Chest Physicians (2013) describes myo-inositol as having low toxicity and promising preclinical and phase 1 data 3

The American College of Medical Genetics and Genomics notes that periconceptional myo-inositol supplementation may reduce neural tube defects, especially in folate-resistant cases, though more research is needed 2
Low levels of myo-inositol (with high glutamine content) on 1H-magnetic resonance spectroscopy are associated with hepatic encephalopathy and can aid in differential diagnosis 4

Even high doses (12 g/day) produce only mild gastrointestinal side effects (nausea, flatus, diarrhea) with severity not increasing with dosage 2
No weight gain, unlike some insulin-sensitizing medications 1, 2
Patients should expect 3-6 months for full clinical benefit 2
Monitor patients on lithium for reduced lithium efficacy and mood instability, as interactions may occur 2

Lifestyle modifications including weight loss should accompany supplementation to enhance treatment effects on metabolic and reproductive abnormalities in PCOS 1

The American Diabetes Association recommends insulin as the first-line treatment for gestational diabetes and type 2 diabetes in pregnancy, as it does not cross the placenta and has well-established long-term safety data 5, 6, 7, 8, 9, 10
Metformin crosses the placenta completely, reaching levels in umbilical cord blood equal to or higher than maternal levels, and is associated with increased BMI, waist-to-height ratio, and waist circumference in children at 4-10 years of age 5, 6, 7, 8, 10
The use of metformin in pregnancy is not recommended as first-line treatment due to concerns about long-term safety and failure to provide adequate glycemic control in 14-46% of women with gestational diabetes 6, 7, 8, 10

Sulfonylureas, such as gliburida, cross the placenta and are associated with increased risk of neonatal hypoglycemia and macrosomia compared to insulin or metformin 6, 8, 10
The American Diabetes Association recommends against the use of gliburida in pregnancy due to its association with adverse outcomes 6, 8, 10

The American College of Obstetricians and Gynecologists does not have specific guidelines for the use of inositol in pregnancy, but the available evidence suggests that it may be safe and effective in reducing the risk of gestational diabetes and hypertensive disorders of pregnancy 9
However, the evidence is limited, and more research is needed to fully understand the benefits and risks of inositol use in pregnancy 9